Skip to Main Content
Yale School of Medicine
About YSM
Faculty
Staff
Students
Residents & Fellows
Patients
Researchers
Alumni
Yale School of Medicine
/
Rheumatology, Allergy & Immunology
MENU
Yale School of Medicine
MENU
Rheumatology, Allergy & Immunology
Rheumatology
Patient Care
Research
Clinical & Translational Research Lab (YR-CTRL)
Immune Profiling
Inflammation and Innate Immunity
In Vivo Imaging Facility
Lupus
Lyme Disease
Microbiome Research
Research Training Faculty
Clinical Trials
Publications
Yale Rheumatology Fellowship Training
Clinical Training
Research Training
Current Fellows and Graduate Information
Faculty
Philanthropy
Allergy & Immunology
Patient Care
Research
Publications
Education & Training
Clinical Training
Research Training
Seminars
Application
Current Fellows
Faculty
Contact Us
Faculty
News & Events
Newsletter
Winter 2023
May 2023
September 2023
December 2023
February 2024
June 2024
September 2024
YSM Home
INFORMATION FOR
About YSM
Faculty
Staff
Students
Residents & Fellows
Patients
Researchers
Alumni
Home
Rheumatology
Research
Clinical & Translational Research Lab (YR-CTRL)
Immune Profiling
Inflammation and Innate Immunity
In Vivo Imaging Facility
Lupus
Lyme Disease
Microbiome Research
Research Training Faculty
Clinical Trials
Publications
Clinical Trials
Phase I
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject with Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and with Other Solid Tumors
Bones and Joints, Soft Tissue
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Breast
A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-negative Recurrent or Metastatic Breast Cancer
Soft Tissue
Testing Ipilimumab and Nivolumab Combination with or without Cabozantinib in People >= 18 Years Old with Advanced Soft Tissue Sarcoma
Prostate, Urinary Bladder
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
Show More
Your browser is antiquated and no longer supported on this website. Please update your browser or switch to Chrome, Firefox or Safari.
You can update your IE here:
https://support.microsoft.com/en-us/help/17621/internet-explorer-downloads
[8330,3053]
{"namedChunks":["modules-page-components-ComponentWrapper","features-clinical-trial-components-ClinicalTrialListing","modules-footer-components-Footer"]}